Bristol-Myers Squibb Co

NYSE:BMYUnited States

Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.

Contact Information

Headquarters

Route 206 And Province Line RoadPRINCETON, NJ, United States 08543

Phone

609-252-4621

Fax

302-655-5049

Executives

Chairman of the Board, Chief Executive Officer, Chief Operating Officer

Christopher Boerner

Executive Vice President, Chief Financial Officer, Member of the Leadership Team

David Elkins

President, Cell Therapy Organization, Member of the Leadership Team

Lynelle Hoch

Chief Human Resource Officer, Executive Vice President, Member of the Leadership Team

Amanda Poole

Executive Vice President, Chief Digital and Technology Officer, Member of the Leadership Team

Greg Meyers